Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
PNC$223.20-10.25(-4.39%)PNC names Alexander Overstrom as CFO, succeeding Robert Reilly5:14:20 PM ETSVM$8.18-0.16(-1.92%)SILVERCORP REPORTS ADJUSTED NET INCOME OF $18.4 MILLION, $0.08 PER SHARE, AND CASH FLOW FROM OPERATING ACTIVITIES OF $62.7 MILLION FOR Q2 FISCAL 20275:06:04 PM ETNET$280.21+35.70(+14.60%)Cloudflare Q3 revenue beats estimates on AI platform demand5:05:25 PM ETTMO$680.00+3.06(+0.45%)Thermo Fisher Scientific Announces Quarterly Dividend5:00:04 PM ETWPM$131.25-0.25(-0.19%)Wheaton Precious Metals Announces Third Quarter 2026 Results and Record Year-to-Date Production, Sales Volume, Revenue, Earnings and Cash Flow5:00:00 PM ETTSX:SAP$41.620.00(0.00%)Saputo Reports Financial Results for the Second Quarter of Fiscal 2027 Ended September 30, 20265:00:00 PM ETNET$280.21+35.70(+14.60%)Cloudflare Stock Surges on Lifted Full-Year Outlook, Third-Quarter Revenue Growth5:00:00 PM ETMNST$45.09-3.66(-7.51%)Monster Beverage Q3 sales beat estimates as marketing investments boost results4:56:44 PM ETEOG$144.89-2.17(-1.48%)UPDATE 2-US shale producer EOG Resources beats profit estimates on higher crude prices4:55:18 PM ETANTUPDATE 1-A&O Shearman's $1.1 billion AI plan builds on law firms' tech investments4:51:58 PM ETDNA$9.83-0.13(-1.31%)Ginkgo Bioworks Q3 revenue falls compared to last year4:51:51 PM ETABX$8.83-0.22(-2.43%)Abacus Global Management Q3 revenue, adjusted EBITDA beat estimates4:51:39 PM ETPRTA$7.89-0.50(-5.96%)Prothena Q3 net loss narrows on lower costs4:51:15 PM ETLRCX$193.04+7.84(+4.23%)BUZZ-Chip firm Lam Research rises after announcing $25 bln stock buyback4:50:28 PM ETEOG$144.89-2.17(-1.48%)EOG Resources Q3 revenue ease past estimates amid strong price realizations4:49:39 PM ETNVDA$181.99+0.39(+0.21%)Stock Market Today, Nov. 5: Nvidia Slides on AI Chip Selloff as Election Uncertainty Weighs4:49:38 PM ETCVS$81.01+1.05(+1.31%)AM Best Places Credit Ratings of CVS Health Corporation’s Aetna Inc. Subsidiaries Under Review with Developing Implications4:49:03 PM ETPTGX$135.26-8.11(-5.66%)Protagonist Therapeutics Q3 revenue surges on Takeda payments4:48:48 PM ETVERX$17.47+1.55(+9.74%)Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years4:47:00 PM ETETOLF$1.22-0.02(-1.61%)Enterprise Prices $1.5 Billion Aggregate Principal Amount of Senior Notes4:47:00 PM ETEPD$36.72+0.10(+0.27%)Enterprise Prices $1.5 Billion Aggregate Principal Amount of Senior Notes4:47:00 PM ETSPG$225.88-2.63(-1.15%)Simon Property Q3 Real Estate FFO per share rises; 2026 outlook raised4:46:33 PM ETEOG$144.89-2.17(-1.48%)UPDATE 1-US shale producer EOG Resources beats quarterly profit estimates on higher crude prices4:45:57 PM ETWFC$84.51-0.29(-0.34%)Wells Fargo & Company (WFC) Presents at BancAnalysts Association of Boston Conference 2026 Transcript4:45:03 PM ET

CSTL · NASDAQ

Castle Biosciences, Inc.

$35.00 -0.78 (-2.18%)

Company overview

Castle Biosciences, Inc. is a commercial-stage diagnostics company focused on providing diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test that identifies the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict the risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers testing services through physicians and their patients.

Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ
Market cap
$1.1B
Employees
784
Headquarters
Friendswood, TX
Website
castlebiosciences.com
CEO
Derek J. Maetzold
Listed
July 25, 2019
P/E
-81.49
Dividend yield
0.00%

Company financials

Revenue
$340M
Gross profit
$262M
Operating income
-$33.3M
EBITDA
-$4.8M
Net income
-$12.8M
EPS
-$0.43
Total assets
$548M
Total debt
$36.7M
Gross margin
77.07%
Net margin
-3.78%
Earnings yield
-1.23%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

16.8822.5528.2233.8939.57
CSTL 1D NASDAQ O36.03H36.43L35.07C35.75+0.61 (+1.74%)Vol462.48K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CSTLCastle Biosciences, Inc. Stock news Castle Biosciences Q3 revenue beats estimates on TissueCypher volume growth Reuters
CSTLCastle Biosciences, Inc. Stock news BRIEF-Castle Biosciences Q3 Revenue USD 102.891 Million Vs. IBES Estimate USD 92.5 Million Reuters
CSTLCastle Biosciences, Inc. Press release Castle Biosciences Reports Third Quarter 2026 Results PR Newswire
CSTLCastle Biosciences, Inc. Press release Castle Biosciences to Participate in Upcoming Investor Conferences Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its... PR Newswire
CSTLCastle Biosciences, Inc. Press release Castle Biosciences to Release Third Quarter 2026 Financial Results and Host Webcast on Thursday, Nov. 5, 2026 Castle Biosciences, Inc. PR Newswire
CSTLCastle Biosciences, Inc. Stock news Castle Biosciences Inc (CSTL) Shares Fall 4.8% -- What GF Score of 80 Tells Investors GuruFocus
CSTLCastle Biosciences, Inc. Press release ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus Castle Biosciences, Inc. PR Newswire
CSTLCastle Biosciences, Inc. Press release Late-Breaking EADV 2026 Data Support Use of DecisionDx®-Melanoma in SLNB Decision-Making and Risk-Aligned Post Surgical Management PR Newswire
CSTLCastle Biosciences, Inc. Press release New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus PR Newswire
CSTLCastle Biosciences, Inc. Press release New Study Highlights Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of AdvanceAD-Tx™ PR Newswire
CSTLCastle Biosciences, Inc. Press release Castle Biosciences to Open New Laboratory Facility in Scottsdale PR Newswire
CSTLCastle Biosciences, Inc. Press release New Decision Modeling Study Demonstrates TissueCypher® Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus PR Newswire
CSTLCastle Biosciences, Inc. Press release JAAD Publication Shows Improved Performance of DecisionDx®-SCC PR Newswire
CSTLCastle Biosciences, Inc. Stock news Castle Biosciences, Inc. (CSTL) Is Up 15.46% in One Week: What You Should Know Zacks Investment Research
CSTLCastle Biosciences, Inc. Stock news Does Castle Biosciences (CSTL) Have the Potential to Rally 31.46% as Wall Street Analysts Expect? Zacks Investment Research
CSTLCastle Biosciences, Inc. Press release Castle Biosciences to Participate in Upcoming Investor Conferences PRNewsWire
CSTLCastle Biosciences, Inc. Stock news Castle Biosciences Raises Outlook as Melanoma, TissueCypher Tests Gain Traction MarketBeat
CSTLCastle Biosciences, Inc. Stock news Comparing Gaxos.ai (NASDAQ:GXAI) and Castle Biosciences (NASDAQ:CSTL) Defense World
CSTLCastle Biosciences, Inc. Press release Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference PRNewsWire
CSTLCastle Biosciences, Inc. Press release Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx™ Test PRNewsWire
See more
FAQ

Questions about Castle Biosciences, Inc.

What does Castle Biosciences, Inc. do?
Castle Biosciences, Inc. is a commercial-stage diagnostics company focused on providing diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test that identifies the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict the risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers testing services through physicians and their patients.
What is CSTL's market cap?
Castle Biosciences, Inc. (CSTL) is a listed stock with a live quote. The latest market cap on this page is $1.1B.
Where is Castle Biosciences, Inc. headquartered?
Castle Biosciences, Inc. is headquartered in Friendswood, TX.
How do I get CSTL news from the API?
Call GET /v1/news?tickers=CSTL. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CSTL news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CSTL, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CSTL price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs